Methodological outlines for assessing the costs of cancer patients care

Cover Page

Cite item

Full Text

Abstract

Introduction. The planning of funding in the public health system and specifically in cancer care remains a challenge for the medical community. Some issues of cancer cost analysis are still not entirely resolved.

Aims. To review the options for analysis of direct cancer costs based on registered follow-up data. 

Methods. The targeting and consensus search methodology was applied to collect the relevant papers from PubMed, Cochrane, E-library (RSCI). 

Results and Discussion. The following options have been identified: 1) using incidence data; 2) using prevalence data; 3) system net and total costs approach; 4) phase approach; 5) cost estimation using censored data. The incidence costs are related to the time of diagnosis. The prevalence costs represent the costs over a fixed calendar period. The net costs can be calculated by subtracting the mean costs across non-cancer patients from the total mean costs across comparable cancer patients. Total costs are defined as the summated costs for cancer patients regardless of whether they are associated with cancer or not. Phase analysis is a variant of estimates based on morbidity data and includes identifying specific periods from the diagnosis when the costs significantly change. Cost estimation using censored data provides for the application of mathematical modeling methods.

Conclusion. The availability of combined cost analysis methods makes it possible to obtain a comprehensive economic assessment for cancer treatment approaches.

About the authors

Dmitry A. Andreev

Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department

Author for correspondence.
Email: dmitry.email08@gmail.com
ORCID iD: 0000-0003-0745-9474

МD., Ph.D., Leading Researcher, Physician-Dermatovenerologist, ScientificClinical Department, Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department, Moscow 115088, Russian Federation.

e-mail: dmitry.email08@gmail.com

Russian Federation

Aleksander A. Zavyalov

Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department

Email: noemail@neicon.ru
ORCID iD: 0000-0003-1825-1871
Russian Federation

Tatiana N. Ermolaeva

Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department

Email: noemail@neicon.ru
ORCID iD: 0000-0002-3615-0292
Russian Federation

References

  1. Karitskiy A.P. Main improvement organizations of federal specia-lized (oncologic) institute as a unit of health system. Pediatr. 2015; 6(4): 116-23. https://doi.org/10.17816/PED64116-123 (in Russian)
  2. Voda A.I., Bostan I. Public health care financing and the costs of cancer care: a cross-national analysis. Cancers (Basel). 2018; 10(4): 117. https://doi.org/10.3390/cancers10040117
  3. National Cancer Institute. Cancer Trends Progress Report. Available at: https://progressreport.cancer.gov (Accessed 20.11.19)
  4. Lipscomb J. Estimating the cost of cancer care in the United States: a work very much in progress. J. Natl. Cancer Inst. 2008; 100(9): 607-10. https://doi.org/10.1093/jnci/djn132
  5. Campos N.G., Kim J.J., Castle P.E., Ortendahl J.D., O’Shea M., Diaz M., et al. Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int. J. Cancer. 2012; 130(11): 2672-84. https://doi.org/10.1002/ijc.26269
  6. Goldie S.J., Kim J.J., Kobus K., Goldhaber-Fiebert J.D., Salomon J., O’Shea M.K., et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine. 2007; 25(33): 6257-70. https://doi.org/10.1016/j.vaccine.2007.05.058
  7. Campos N.G., Castle P.E., Wright T.C., Kim J.J. Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage. Int. J. Cancer. 2015; 137(9): 2208-19. https://doi.org/10.1002/ijc.29594
  8. Hoyle M., Crathorne L., Peters J., Jones-Hughes T., Cooper C., Napier M., et al. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Health Technol. Assess. 2013; 17(14): 1-237. https://doi.org/10.3310/hta17140
  9. Collins R., Fenwick E., Trowman R., Perard R., Norman G., Light K., et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol. Assess. 2007; 11(2): iii-iv, xv-xviii, 1-179. https://doi.org/10.3310/hta11020
  10. Jacobs V.R., Thoedtmann J., Brunner B., Kiechle M. An economic model to reduce the cost of chemotherapy for gynecologic cancer. Int. J. Fertil Womens Med. 2004; 49(6): 274-7.
  11. Lipscomb J., Donaldson M.S., Hiatt R.A. Cancer outcomes research and the arenas of application. J. Natl. Cancer Inst. Monogr. 2004; (33): 1-7. https://doi.org/10.1093/jncimonographs/lgh038
  12. You C.H., Kang S., Kwon Y.D. The economic burden of breast cancer survivors in Korea: A descriptive study using a 26-month micro-costing cohort approach. Asian Pac. J. Cancer Prev. 2019; 20(7): 2131-7. https://doi.org/10.31557/APJCP.2019.20.7.2131
  13. Lairson D.R., Wu C.F., Chan W., Fu S., Hoffman K.E., Pettaway C.A. Mean treatment cost of incident cases of penile cancer for privately insured patients in the United States. Urol. Oncol. 2019; 37(4): 294.e17-294.e25. https://doi.org/10.1016/j.urolonc.2019.01.004
  14. Khatiwoda S.R., Dhungana R.R., Sapkota V.P., Singh S. Estimating the direct cost of cancer in Nepal: a cross-sectional study in a tertiary cancer hospital. Front. Public Health. 2019; 7: 160. https://doi.org/10.3389/fpubh.2019.00160
  15. Jeon S.M., Kwon J.W., Choi S.H., Park H.Y. Economic burden of lung cancer: A retrospective cohort study in South Korea, 2002-2015. PLoS One. 2019; 14(2): e0212878. https://doi.org/10.1371/journal.pone.0212878
  16. McGuire A., Martin M., Lenz C., Sollano J.A. Treatment cost of non-small cell lung cancer in three European countries: comparisons across France, Germany, and England using administrative databases. J. Med. Econ. 2015; 18(7): 525-32. https://doi.org/10.3111/13696998.2015.1032974
  17. Carrera P.M., Kantarjian H.M., Blinder V.S. The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J. Clin. 2018; 68(2): 153-65. https://doi.org/10.3322/caac.21443
  18. Bonakdar Tehrani A., Carroll N.V. The medicaid rebate: chan-ges in oncology drug prices after the affordable care act. Appl. Health Econ. Health Policy. 2017; 15(4): 513-20. https://doi.org/10.1007/s40258-017-0314-1
  19. Baker M.S., Kessler L.G., Urban N., Smucker R.C. Estimating the treatment costs of breast and lung cancer. Med. Care. 1991; 29(1): 40-9. https://doi.org/10.1097/00005650-199101000-00004
  20. Brown M.L., Riley G.F., Schussler N., Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med. Care. 2002; 40(8 Suppl.): IV-104-17. https://doi.org/10.1097/00005650-200208001-00014
  21. Taplin S.H., Barlow W., Urban N., Mandelson M.T., Timlin D.J., Ichikawa L., et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J. Natl. Cancer Inst. 1995; 87(6): 417-26. https://doi.org/10.1093/jnci/87.6.417
  22. Attema A.E., Brouwer W.B.F., Claxton K. Discounting in economic evaluations. Pharmacoeconomics. 2018; 36(7): 745-58. https://doi.org/10.1007/s40273-018-0672-z
  23. Barlow W.E. Overview of methods to estimate the medical costs of cancer. Med. Care. 2009; 47(7 Suppl. 1): S33-6. https://doi.org/10.1097/MLR.0b013e3181a2d847
  24. Lin D.Y., Feuer E.J., Etzioni R., Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics. 1997; 53(2): 419-34.
  25. Piccinni C., Dondi L., Ronconi G., Calabria S., Pedrini A., Esposito I., et al. HR+/HER2- metastatic breast cancer: epidemiology, prescription patterns, healthcare resource utilisation and costs from a Large Italian Real-World Database. Clin. Drug Investig. 2019; 39(10): 945-51. https://doi.org/10.1007/s40261-019-00822-4
  26. Shih Y.T., Xu Y., Chien C.R., Kim B., Shen Y., Li L., et al. Rising economic burden of renal cell carcinoma among elderly patients in the USA: Part II-an updated analysis of SEER-Medicare data. Pharmacoeconomics. 2019; 37(12): 1495-507. https://doi.org/10.1007/s40273-019-00824-2
  27. Chang S., Long S.R., Kutikova L., Bowman L., Finley D., Crown W.H., et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J. Clin. Oncol. 2004; 22(17): 3524-30. https://doi.org/10.1200/JCO.2004.10.170
  28. Alefan Q., Malhees R., Mhaidat N. Direct medical cost associated with colorectal cancer in north of Jordan. Curr. Probl. Cancer. 2017; 41(5): 371-81. https://doi.org/10.1016/j.currproblcancer.2017.05.001
  29. Joseph A.K., Mark T.L., Mueller C. The period prevalence and costs of treating nonmelanoma skin cancers in patients over 65 years of age covered by medicare. Dermatol. Surg. 2001; 27(11): 955-9. https://doi.org/10.1046/j.1524-4725.2001.01106.x
  30. Pisu M., Henrikson N.B., Banegas M.P., Yabroff K.R. Costs of cancer along the care continuum: What we can expect based on recent literature. Cancer. 2018; 124(21): 4181-91. https://doi.org/10.1002/cncr.31643
  31. Deshmukh A.A., Zhao H., Franzini L., Lairson D.R., Chiao E.Y., Das P., et al. Total lifetime and cancer-related costs for elderly patients diagnosed with anal cancer in the United States. Am. J. Clin. Oncol. 2018; 41(2): 121-7. https://doi.org/10.1097/COC.0000000000000238
  32. Calhoun E.A., Bennett C.L. Evaluating the total costs of cancer. The Northwestern University Costs of Cancer Program. Onco-logy (Williston Park). 2003; 17(1): 109-14; discussion 19-21.
  33. Boltz M.M., Hollenbeak C.S., Schaefer E., Goldenberg D., Saunders B.D. Attributable costs of differentiated thyroid cancer in the elderly Medicare population. Surgery. 2013; 154(6): 1363-9; discussion 9-70. https://doi.org/10.1016/j.surg.2013.06.042
  34. Yli-Uotila T., Kaunonen M., Pylkkanen L., Suominen T. The need for social support provided by the non-profit cancer societies throughout different phases in the cancer trajectory and its integration into public healthcare. Eur. J. Oncol. Nurs. 2016; 21: 97-104. https://doi.org/10.1016/j.ejon.2016.02.004
  35. Sheehan D.F., Criss S.D., Chen Y., Eckel A., Palazzo L., Tramontano A.C., et al. Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare. Cancer Med. 2019; 8(1): 94-103. https://doi.org/10.1002/cam4.1896
  36. Tramontano A.C., Chen Y., Watson T.R., Eckel A., Hur C., Kong C.Y. Esophageal cancer treatment costs by phase of care and treatment modality, 2000-2013. Cancer Med. 2019; 8(11): 5158-72. https://doi.org/10.1002/cam4.2451
  37. Adams M. Information and education across the phases of cancer care. Semin. Oncol. Nurs. 1991; 7(2): 105-11. https://doi.org/10.1016/0749-2081(91)90088-7
  38. Bercow A.S., Chen L., Chatterjee S., Tergas A.I., Hou J.Y., Burke W.M., et al. Cost of care for the initial management of ovarian cancer. Obstet. Gynecol. 2017; 130(6): 1269-75. https://doi.org/10.1097/AOG.0000000000002317
  39. Vyas A., Madhavan S.S., Sambamoorthi U., Pan X.L., Regier M., Hazard H., et al. Healthcare utilization and costs during the initial phase of care among elderly women with breast cancer. J. Natl. Compr. Canc. Netw. 2017; 15(11): 1401-9. https://doi.org/10.6004/jnccn.2017.0167
  40. de Oliveira C., Pataky R., Bremner K.E., Rangrej J., Chan K.K., Cheung W.Y., et al. Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer. 2016; 16(1): 809. https://doi.org/10.1186/s12885-016-2835-7
  41. Liu N., Mittmann N., Coyte P.C., Hancock-Howard R., Seung S.J., Earle C.C. Phase-specific healthcare costs of cervical cancer: estimates from a population-based study. Am. J. Obstet. Gynecol. 2016; 214(5): 615.e1-615.e11. https://doi.org/10.1016/j.ajog.2015.11.021
  42. Rozman L.M., Campolina A.G., Lopez R.M., Chiba T., De Soarez P.C. Palliative cancer care: costs in a Brazilian quaternary hospital. BMJ Support. Palliat. Care. 2019; bmjspcare-2019-001809. https://doi.org/10.1136/bmjspcare-2019-001809
  43. Yennurajalingam S., Lu Z., Reddy S.K., Rodriguez E.C., Nguyen K., Waletich-Flemming M.J., et al. Patterns of opioid prescription, use, and costs among patients with advanced cancer and inpatient palliative care between 2008 and 2014. J. Oncol. Pract. 2019; 15(1): e74-e83. https://doi.org/10.1200/JOP.18.00205
  44. Kaye D.R., Min H.S., Herrel L.A., Dupree J.M., Ellimoottil C., Miller D.C. Costs of cancer care across the disease continuum. Oncologist. 2018; 23(7): 798-805. https://doi.org/10.1634/theoncologist.2017-0481
  45. Thein H.H., Jembere N., Thavorn K., Chan K.K.W., Coyte P.C., de Oliveira C., et al. Estimates and predictors of health care costs of esophageal adenocarcinoma: a population-based cohort study. BMC Cancer. 2018; 18(1): 694. https://doi.org/10.1186/s12885-018-4620-2
  46. Brown M.L., Riley G.F., Potosky A.L., Etzioni R.D. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med. Care. 1999; 37(12): 1249-59. https://doi.org/10.1097/00005650-199912000-00008
  47. Yabroff K.R., Lamont E.B., Mariotto A., Warren J.L., Topor M., Meekins A., et al. Cost of care for elderly cancer patients in the United States. J. Natl. Cancer Inst. 2008; 100(9): 630-41. https://doi.org/10.1093/jnci/djn103
  48. Bashlakova E.E., Andreev D.A., Khachanova N.V., Davydovskaya M.V. Registries. Types of registries. Registries of Hemophilia (review). Vrach i informatsionnye tekhnologii. 2018; (1): 33-42. (in Russian)
  49. Andreev D.A., Khachanova N.V., Kokushkin K.A., Davydovskaya M.V. Multiple sclerosis registries as a vital element in the transition to the value-vased healthcare. Problemy standartizatsii v zdravookhranenii. 2018; (3-4): 35-45. https://doi.org/10.26347/1607-2502201803-04035-045 (in Russian)
  50. Andreev D.A., Bashlakova E.E., Khachanova N.V., Davydovskaya M.V. Cystic fibrosis patient registries: domestic and foreign experience. Pediatricheskaya farmakologiya. 2017; 14(2): 115-26. https://doi.org/10.15690/rf.v14i2.1726 (in Russian)
  51. Zhao H., Bang H., Wang H., Pfeifer P.E. On the equivalence of some medical cost estimators with censored data. Stat. Med. 2007; 26(24): 4520-30. https://doi.org/10.1002/sim.2882
  52. Quick H. Estimating county-level mortality rates using highly censored data from CDC WONDER. Prev. Chronic Dis. 2019; 16: E76. https://doi.org/10.5888/pcd16.180441
  53. Hsu C.Y., Chen C.H., Hsu K.N., Lu Y.H. A useful design utilizing the information fraction in a group sequential clinical trial with censored survival data. Biometrics. 2019; 75(1): 133-43. https://doi.org/10.1111/biom.12925
  54. Costa S., Scott D.W., Steidl C., Peacock S.J., Regier D.A. Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia. Curr. Oncol. 2019; 26(2): 108-13. https://doi.org/10.3747/co.26.4565
  55. Sun L., Legood R., Dos-Santos-Silva I., Gaiha S.M., Sadique Z. Global treatment costs of breast cancer by stage: A systematic review. PLoS One. 2018; 13(11): e0207993. https://doi.org/10.1371/journal.pone.0207993
  56. Lairson D.R., Fu S., Chan W., Xu L., Shelal Z., Ramondetta L. Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas. Gynecol. Oncol. 2017; 145(1): 108-13. https://doi.org/10.1016/j.ygyno.2017.02.011
  57. Andreev D.A., Khachanova N.V., Stepanova V.N., Bashlakova E.E., Evdoshenko E.P., Davydovskaya M.V. Standardized modeling of the chronic disease progression (review). Problemy standartizatsii v zdravookhranenii. 2017; (9-10): 12-24. https://doi.org/10.26347/1607-2502201709-10012-024 (in Russian)
  58. Yu T., Wu L., Gilbert P. New approaches for censored longitudinal data in joint modelling of longitudinal and survival data, with application to HIV vaccine studies. Lifetime Data Anal. 2019; 25(2): 229-58. https://doi.org/10.1007/s10985-018-9434-7
  59. Hwang J.S., Hu T.H., Lee L.J., Wang J.D. Estimating lifetime medical costs from censored claims data. Health Econ. 2017; 26(12): e332-e44. https://doi.org/10.1002/hec.3512
  60. Zhao H., Tian L. On estimating medical cost and incremental cost-effectiveness ratios with censored data. Biometrics. 2001; 57(4): 1002-8. https://doi.org/10.1111/j.0006-341x.2001.01002.x
  61. Basu A., Manning W.G. Estimating lifetime or episode-of-illness costs under censoring. Health Econ. 2010; 19(9): 1010-28. DOI: http://doi.org/10.1002/hec.1640
  62. Yoon G., Jiang W., Liu L., Shih Y.T. Simple quasi-Bayes approach for modeling mean medical costs. Int. J. Biostat. 2019; 16(1): /j/ijb.2020.16.issue-1/ijb-2018-0122/ijb-2018-0122.xml. https://doi.org/10.1515/ijb-2018-0122
  63. O’Hagan A., Stevens J.W. On estimators of medical costs with censored data. J. Health Econ. 2004; 23(3): 615-25. https://doi.org/10.1016/j.jhealeco.2003.06.006
  64. Wang X., Beste L.A., Maier M.M., Zhou X.H. Double robust estimator of average causal treatment effect for censored medical cost data. Stat. Med. 2016; 35(18): 3101-16. https://doi.org/10.1002/sim.6876
  65. Goldie S.J., Daniels N. Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparities. J. Natl. Cancer Inst. 2011; 103(18): 1373-86. https://doi.org/10.1093/jnci/djr303
  66. Jabbour E.J., Mendiola M.F., Lingohr-Smith M., Lin J., Makenbaeva D. Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US. J. Med. Econ. 2019; 22(11): 1113-8. https://doi.org/10.1080/13696998.2019.1618316
  67. Wijeysundera H.C., Wang X., Tomlinson G., Ko D.T., Krahn M.D. Techniques for estimating health care costs with censored data: an overview for the health services researcher. Clinicoecon. Outcomes Res. 2012; 4: 145-55. https://doi.org/10.2147/CEOR.S31552
  68. Vock D.M., Wolfson J., Bandyopadhyay S., Adomavicius G., Johnson P.E., Vazquez-Benitez G., et al. Adapting machine learning techniques to censored time-to-event health record data: A general-purpose approach using inverse probability of censoring weighting. J. Biomed. Inform. 2016; 61: 119-31. https://doi.org/10.1016/j.jbi.2016.03.009

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Andreev D.A., Zavyalov A.A., Ermolaeva T.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ:  ПИ № ФС77-50668 от 13.07.2012 г.